Kbi-092 !exclusive! -

Unlike traditional therapies that target a single pathway, KBI-092 is engineered for a "two-pronged" attack on leukemia cells. Its therapeutic efficacy stems from the selective inhibition of two critical proteins:

The drug has received clearance from both the FDA (United States) and the NMPA (China) to begin Phase 1 clinical trials. KBI-092

The development of KBI-092 involves high-level collaboration within the biopharmaceutical ecosystem. , a leading global Contract Development and Manufacturing Organization (CDMO) , is frequently involved in scaling the production of complex biologics and small molecules for clinical trials. Unlike traditional therapies that target a single pathway,